QT Interval Effects Study of Oral FXS5626 Tablets

Phase 1 Not yet recruiting 28 enrolled Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc interval of a single oral dose of FXS5626 in healthy subjects.

Timeline

Start: 2026-08-05
Primary completion: 2026-09-25
Completion: 2026-09-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FXS5626	Unknown	75 mg	Oral
Subject	FXS5626	Unknown	250 mg	Oral
Subject	FXS5626	Unknown	400 mg	Oral

Indications

No indication recorded.